Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.40 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12701773 | 0.86 | NOS3 (0.41) | P2RX3P2RX2NOS2NOS3NOS1 | |
| SCHEMBL16414275 | 0.77 | P2RX3 (0.40) | P2RX3P2RX2NOS2NOS3NOS1 | |
| SCHEMBL16414472 | 0.74 | NOS3 (0.44) | NOS2NOS3NOS1LMNAGABRA1 | |
| SCHEMBL16414299 | 0.71 | DHFR (0.34) | NOS2NOS3NOS1LMNADPP4 | |
| SCHEMBL16414484 | 0.69 | DHFR (0.32) | P2RX3P2RX2 | |
| SCHEMBL25654726 | 0.68 | NOS3 (0.33) | P2RX3P2RX2NOS2NOS3NOS1 | |
| SCHEMBL16414455 | 0.68 | GABRP (0.41) | NOS2NOS3NOS1LMNAGABRA1 | |
| SCHEMBL27884568 | 0.67 | P2RX3 (0.35) | P2RX3P2RX2NOS2NOS3NOS1 | |
| SCHEMBL16414388 | 0.67 | GABRA1 (0.41) | P2RX3P2RX2ALDH1A1GABRA1GABRB2 | |
| SCHEMBL14257080 | 0.67 | LMNA (0.59) | P2RX3P2RX2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174906-B2 | Process for producing optically active secondary alcohol | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2015-11-03 | — | — | US | claimed |
| EP-2865446-A1 | Process for producing optically active secondary alcohol | Kanto Kagaku Kabushiki Kaisha (JP) | 2015-04-29 | — | — | EP | claimed |
| US-20150031920-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SECONDARY ALCOHOL | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2015-01-29 | — | — | US | claimed |
| EP-2865446-B1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SECONDARY ALCOHOL | KANTO KAGAKU (JP) | 2021-09-22 | — | — | EP | disclosed |
| US-9174906-B2 | Process for producing optically active secondary alcohol | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2015-11-03 | — | — | US | disclosed |
| EP-2865446-A1 | Process for producing optically active secondary alcohol | Kanto Kagaku Kabushiki Kaisha (JP) | 2015-04-29 | — | — | EP | disclosed |
| US-20150031920-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SECONDARY ALCOHOL | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2015-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031920-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SECONDARY ALCOHOL | ADH1A, ADH1C, ADH5 | P2RX3 2293/4885P2RX2 1946/4885NOS2 2953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.